DTC Ad Final Rule Means Reliance On PhRMA Program Risks Enforcement Action – Azar
Executive Summary
Nevertheless, the Pharmaceutical Research and Manufacturers of America announces enhancement of its drug pricing disclosures voluntary program, a Medicines Assistance Tool website that links to individual company sites, in response to the US rule.
You may also be interested in...
After DTC Rule Tossed Out In Court, Attention Turns (Again) To Congress
HHS lacks authority to require drug price disclosures in TV ads, judge rules. Even if legislation were to explicitly give the Trump Administration such authority, First Amendment issues would still linger.
Drug Pricing Policy Show Moves Into Next Act With Biopharmas' Suit Against DTC Ad Rule
Merck, Lilly, Amgen join advertisers in suit against HHS; rule helped Trump administration spotlight industry pricing practices but potential impact has always been unclear.
First Amendment Challenge To DTC Rule Unlikely From Industry; For Now, It Is 'Comply With Context'
DTC rule is a good fight to lose: it is a high-profile response to pricing, but will have a low impact – and is certainly a less painful solution than many of the alternatives.